Processa Pharmaceuticals, Inc. — Director's Dealing 2022

Jul 21, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2022-07-19

Reporting Person: Neal James R (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-07-19	Restricted Stock	$0	A	17797	Acquired		Common Stock (17797)	Direct

Footnotes

F1: The restricted stock vest on the earlier of one year from the grant date or the next annual meeting of stockholders.